Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;42(4):474-486.
doi: 10.1177/0272989X211049213. Epub 2021 Nov 7.

A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing

Affiliations

A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing

Aasthaa Bansal et al. Med Decis Making. 2022 May.

Abstract

Background: Patient surveillance using repeated biomarker measurements presents an opportunity to detect and treat disease progression early. Frequent surveillance testing using biomarkers is recommended and routinely conducted in several diseases, including cancer and diabetes. However, frequent testing involves tradeoffs. Although surveillance tests provide information about current disease status, the complications and costs of frequent tests may not be justified for patients who are at low risk of progression. Predictions based on patients' earlier biomarker values may be used to inform decision making; however, predictions are uncertain, leading to decision uncertainty.

Methods: We propose the Personalized Risk-Adaptive Surveillance (PRAISE) framework, a novel method for embedding predictions into a value-of-information (VOI) framework to account for the cost of uncertainty over time and determine the time point at which collection of biomarker data would be most valuable. The proposed sequential decision-making framework is innovative in that it leverages the patient's longitudinal history, considers individual benefits and harms, and allows for dynamic tailoring of surveillance intervals by considering the uncertainty in current information and estimating the probability that new information may change treatment decisions, as well as the impact of this change on patient outcomes.

Results: When applied to data from cystic fibrosis patients, PRAISE lowers costs by allowing some patients to skip a visit, compared to an "always test" strategy. It does so without compromising expected survival, by recommending less frequent testing among those who are unlikely to be treated at the skipped time point.

Conclusions: A VOI-based approach to patient monitoring is feasible and could be applied to several diseases to develop more cost-effective and personalized strategies for ongoing patient care.

Highlights: In many patient-monitoring settings, the complications and costs of frequent tests are not justified for patients who are at low risk of disease progression. Predictions based on patient history may be used to individualize the timing of patient visits based on evolving risk.We propose Personalized Risk-Adaptive Surveillance (PRAISE), a novel method for personalizing the timing of surveillance testing, where prediction modeling projects the disease trajectory and a value-of-information (VOI)-based pragmatic decision-theoretic framework quantifies patient- and time-specific benefit-harm tradeoffs.A VOI-based approach to patient monitoring could be applied to several diseases to develop more personalized and cost-effective strategies for ongoing patient care.

Keywords: dynamic decision making; dynamic prediction; personalized medicine; value of information.

PubMed Disclaimer

Figures

Figure 1/
Figure 1/
Predicted biomarker value with uncertainty
Figure 2/
Figure 2/
Two-stage decision problem at timet
Figure 3/
Figure 3/
Sequential decision-making, i.e. sliding decision tree repeated at each visit
Figure 4/
Figure 4/
EVIST (in years) for individual subjects in the low baseline FEV1% (<40%) and high baseline FEV1% (>40%) groups

Similar articles

Cited by

References

    1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. Version 2 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed September 28, 2016.
    1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: rectal cancer. Version 2 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed September 28, 2016.
    1. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, and Benson III AB (2013). Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer. American Society of Clinical Oncology Clinical Practice Guideline Endorsement; 31(35): 4465–4470. DOI:10.1200/JCO.2013.50.7442 - DOI - PubMed
    1. El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, Cannady RS, Wong SL, Rose J, Barbour AL, Stein KD, Sharpe KB, Brooks DD, Cowens-Alvarado RL (2015). American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer Journal for Clinicians; 65: 427–455. DOI:10.3322/caac.21286 - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: prostate cancer. Version 1 2015. Available from: http://www.nccn.org./professionals/physician_gls/pdf/prostate.pdf. Accessed September 28, 2016.

Publication types